Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice

被引:52
作者
Dimas, Konstantinos
Hatziantoniou, Sophia
Tseleni, Sophia
Khan, Humaira
Georgopoulos, Aristidis
Alevizopoulos, Konstantinos
Wyche, James H.
Pantazis, Panayotis
Demetzos, Costas
机构
[1] Acad Athens, Fdn Biomed Res, Lab Pharmacol & Pharmacotechnol, Athens 11527, Greece
[2] Univ Athens, Sch Pharm, Dept Pharmaceut Technol, Athens, Greece
[3] Univ Athens, Sch Med, Dept Pathol, Athens, Greece
[4] Medexis SA, Athens, Greece
[5] Univ Oklahoma, Ctr Hlth Sci, OU Canc Inst, Oklahoma City, OK USA
关键词
plant product; Labdane diterpene; sclareol; apoptosis; tumor suppression;
D O I
10.1007/s10495-006-0026-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Labd-14-ene-8, 13-diol (sclareol) is a labdane-type diterpene, which has demonstrated significant cytotoxic activity against human leukemic cell lines, but its effect on solid tumor-derived cells is uknown. Here, we demonstrate that addition of sclareol to cultures of human colon cancer HCT116 cells results in inhibition of DNA synthesis, arrest of cells at the G(1) phase of the cell cycle, activation of caspases-8, -9, PARP degradation, and DNA fragmentation, events characteristic of induction of apoptosis. Intraperitoneal (ip) administration of sclareol alone, at the maximum tolerated dose, was unable to induce suppression of growth of HCT116 tumors established as xenografts in immunodeficient SCID mice. In contrast, ip administration of liposome-encapsulated sclareol, following a specific schedule, induced suppression of tumor growth by arresting tumor cell proliferation as assessed by detecting the presence of the cell proliferation-associated nuclear protein, Ki67, in thin tumor sections. These findings suggest that sclareol incorporated into liposomes may possess chemotherapeutic potential for the treatment of colorectal and other types of human cancer.
引用
收藏
页码:685 / 694
页数:10
相关论文
共 45 条
[1]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[2]  
Balan KV, 2005, IN VIVO, V19, P93
[3]  
BALAN KV, 2006, IN PRESS PHYTOMEDICI
[4]   Cell-specific targeting of lipid-based carriers for ODN and DNA [J].
Bartsch, M ;
Weeke-Klimp, AH ;
Meijer, DKF ;
Scherphof, GL ;
Kamps, JAAM .
JOURNAL OF LIPOSOME RESEARCH, 2005, 15 (1-2) :59-92
[5]   Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer [J].
Batist, G ;
Ramakrishnan, G ;
Rao, CS ;
Chandrasekharan, A ;
Gutheil, J ;
Guthrie, T ;
Shah, P ;
Khojasteh, A ;
Nair, MK ;
Hoelzer, K ;
Tkaczuk, K ;
Park, YC ;
Lee, LW .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1444-1454
[6]   MONOCLONAL-ANTIBODIES AGAINST RECOMBINANT PARTS OF THE KI-67 ANTIGEN (MIB-1 AND MIB-3) DETECT PROLIFERATING CELLS IN MICROWAVE-PROCESSED FORMALIN-FIXED PARAFFIN SECTIONS [J].
CATTORETTI, G ;
BECKER, MHG ;
KEY, G ;
DUCHROW, M ;
SCHLUTER, C ;
GALLE, J ;
GERDES, J .
JOURNAL OF PATHOLOGY, 1992, 168 (04) :357-363
[7]  
Chen Y., 2004, Current Drug Delivery, V1, P361, DOI 10.2174/1567201043334542
[8]   Antioxidant intervention as a route to cancer prevention [J].
Collins, AR .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (13) :1923-1930
[9]  
Connolly JD, 1991, DICT TERPENOIDS
[10]  
Corbett Th. VF, 1997, ANTICANCER DRUG DEV, P75